Innovation Ventures ☰
  • Partnering Opportunities
  • Innovator
  • Partner
  • Investor
  • About
Genetic Diseases

Novel Treatment to Ensure Efficacious Dosage for Multiple, Rare Genetic Diseases

Optimal dosing regimen for treating seizures and self-aggressive behavior


Technology Overview

Clinicians use a common, FDA approved drug to treat symptoms such as seizures and self-aggressive behavior. In some genetically identified patients, too low of a dose is not effective and too high of a dose is not optimal. Sub-optimal dosing may also cause sleep problems, dyslipidemia, diabetes, and growth problems.  We are working on refining the dosing regimen for patient sub-populations.  

Applications

Smith Kingsmore Syndrome, Tuberous sclerosis, PMSE, and other similar genetic diseases.

Advantages

  • Repurposing an FDA approved drug.
  • A biomarker for optimal dosing.
  • Strategy likely applies to other mTORopathies.

Investigator Overview

John Hogenesch, PhD & Carlos E. Prada, MD, Co-Director, Rasopathy Program

Technology ID

2019-0505

Business Opportunity

Exclusive License

Technology Type

Small Molecule

Stage of Development

Pre-Clinical - In Vivo


Download PDF


Contact Innovation Ventures

partnering@cchmc.org 1.513.636.4285
  • Partnering Opportunities
  • Innovator
  • Partner
  • Investor
  • About

Innovation Ventures | Partnering to Change the Outcome

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4285

© 1999-2021 Cincinnati Children's Hospital Medical Center